Effect of SSRIs on Response to Psilocybin Therapy

This open-label, single-arm trial (n=30) aimed to evaluate the effect of length of time on selective serotonin reuptake inhibitors (SSRIs) on the response to psilocybin-assisted therapy in individuals with mild-moderate Major Depressive Disorder (MDD).

All participants received a single dose of 25mg of psilocybin in a therapeutic setting. The study enrolled individuals with varying lengths of time on SSRI therapy, stratified into four groups based on the duration of SSRI treatment.

The primary outcome measure was assessed using the Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR-16), with secondary outcomes including response and remission rates, depression severity measured by MADRS, and safety assessments. The study started on January 1, 2023, and was expected to be completed by March 14, 2023, but was ultimately withdrawn.

Topic Depression
Compound Psilocybin
Country Canada
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Cybin
Cybin is a for-profit company that aims to deliver psychedelics (psilocybin) via a sublingual delivery mechanism. The company aims to start clinical trials within the year (2021). It has raised $98 million US.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.